Modal close

Dear Democracy Now! visitor,

You turn to Democracy Now! for ad-free news you can trust. Maybe you come for our daily headlines. Maybe you come for in-depth stories that expose corporate and government abuses of power. Democracy Now! brings you crucial reporting like our coverage from the front lines of the Dakota Access pipeline protests or news about this unprecedented US presidential election—and our coverage is never paid for by the oil and gas companies or the campaigns and superPACs. We produce our daily news hour at a fraction of the budget of a commercial news operation—all without ads, government funding or corporate sponsorship. How? This model of news depends on your support. Today, less than 1% of our visitors support Democracy Now! with a donation each year. If even 3% of our website visitors donated just $8 per month, we could cover our basic operating expenses for a year. Pretty amazing right? If you visit us daily or weekly or even just once a month, now is a great time to make your monthly contribution.

Non-commercial news needs your support.

We rely on contributions from you, our viewers and listeners to do our work. If you visit us daily or weekly or even just once a month, now is a great time to make your monthly contribution.

Please do your part today.

Topics

New AIDS Medication

July 11, 1996
Story
WATCH FULL SHOW

Topics

Guests

BOB LEDERER

Senior Editor at POZ, a magazine by for and about people living with HIV

The International AIDS Conference in Vancouver, British Columbia, Canada is wrapping up. The most hopeful news at the conference is the development of a promising new category of medications called protease inhibitors. Some believe these drugs could turn HIV into a manageable rather than deadly disease, but the medication is extremely expensive and completely out of reach for the vast majority of people living with AIDS around the world.


The original content of this program is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License. Please attribute legal copies of this work to democracynow.org. Some of the work(s) that this program incorporates, however, may be separately licensed. For further information or additional permissions, contact us.